SEZINasdaq StockholmHealth CareIFRS · SEK

Senzime

Senzime is a global medical technology company specializing in algorithm-based patient monitoring systems aimed at reducing anesthesia-related complications. The company's flagship product, the TetraGraph system, is used in thousands of operating rooms worldwide to provide precision-based monitoring during and after surgery. Senzime collaborates with leading academic institutions and operates in over 30 markets, with subsidiaries in the US and Germany. The company is listed on the Nasdaq Main Market Stockholm and is recognized for its rapid growth and innovation in medical technology.

Ask about the company
Revenue104m SEK
+77.9 %y/y
Operating profit (EBIT)-122.6bn SEK
−98,707.8 %y/y
EBIT margin-117,835.7%
−117,623.5 ppy/y
Net income-137m SEK
−15.7 %y/y

Fiscal year 2025 · change from previous year

Development 2021–2025

-125,000-100,000-75,000-50,000-25,000025,000m SEK2021: 11 m SEK2021: EBIT -84 m SEK20212022: 14 m SEK2022: EBIT -134 m SEK20222023: 36 m SEK2023: EBIT -137 m SEK20232024: 58 m SEK2024: EBIT -124 m SEK20242025: 104 m SEK2025: EBIT -122,575 m SEK2025104-122,575
RevenueOperating profit (EBIT)
Ask Clarifo about Senzime

Business

Share of revenue
Neuromuscular Monitoring Systems50 %

Includes TetraGraph systems for precision-based patient monitoring.

Software Solutions20 %

Includes EMGINE™ Sirius software for enhanced monitoring capabilities.

Disposable Sensors20 %

Single-use sensors for patient monitoring during surgeries.

Licensing and Partnerships10 %

Revenue from licensing and distribution agreements.

Customers

Senzime's customers primarily include hospitals and healthcare institutions that require advanced patient monitoring solutions. The company's products are designed to improve surgical outcomes by providing real-time data on neuromuscular function, which is critical for anesthesiologists. Senzime collaborates with leading academic medical centers, such as Mayo Clinic and Harvard, to ensure its systems meet the latest clinical guidelines. The company also targets international markets through partnerships and subsidiaries, expanding its reach to over 30 countries.

Hospitals

Purchase TetraGraph systems for precision-based monitoring to improve surgical outcomes.

Academic Medical Centers

Collaborate on research and use systems to meet clinical guidelines.

International Distributors

License and distribute Senzime products in various regions.

Strategy

Senzime's strategic priorities include accelerating growth and achieving profitability by 2026. The company focuses on expanding its market presence through strategic partnerships and increasing sales of its TetraGraph systems. Senzime aims to enhance its product offerings with continuous innovation and development of new software solutions. The company also seeks to optimize its financial resources to support long-term strategic initiatives and maintain a stable cost structure.

Accelerate growthMedium term

To surpass revenue milestones and strengthen market position.

Achieve profitabilityLong term

To ensure sustainable financial performance.

Product innovationShort term

To maintain competitive edge and meet clinical needs.

Geography

Senzime operates globally, with commercial activities in over 30 markets. The company has subsidiaries in the US and Germany, which are key markets for its growth strategy. Senzime's products are distributed through licensing and partnerships in other regions, allowing it to expand its international presence. The company's operations are not affected by geopolitical tensions in regions like Russia and the Middle East, as it has no direct business in these areas.

Risks

Senzime faces several risks, including financial and operational challenges. The introduction of new US tariffs poses a significant uncertainty, potentially impacting gross margins. Currency fluctuations, particularly the stronger Swedish krona, can negatively affect sales. The company also needs to manage its financial resources carefully to support growth initiatives. Additionally, as a medical technology company, Senzime must navigate regulatory changes and ensure compliance with clinical guidelines.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →US tariffs1Currency fluctuations2Regulatory changes3
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. US tariffsImpact: HighLikelihood: High

    Increase in costs affecting gross margins.

  2. Currency fluctuationsImpact: MediumLikelihood: High

    Stronger Swedish krona negatively impacts sales.

  3. Regulatory changesImpact: MediumLikelihood: Low

    Need to comply with evolving clinical guidelines.

Ask Clarifo about Senzime

Accounting

Judgemental items
Currency effects recognition

Impacts net financial items and comparability with previous years.

Alternative performance measures

Provide clearer insights into financial health.

Similar listed companies

Publicly listed companies with a comparable business focus.

Getinge

GETI-B · Health Care

Hyperfine, Inc.

HYPR · Electromedical & Electrotherapeutic Apparatus

Senseonics Holdings, Inc.

SENS · Industrial Instruments For Measurement, Display, and Control

Sensus Healthcare, Inc.

SRTS · Surgical & Medical Instruments & Apparatus

Halozyme Therapeutics, Inc

HALO · Biological Products, (No Diagnostic Substances)

ENvue Medical, Inc.

FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Last updated: 24/09/2026

Senzime (SEZI) Revenue, Earnings & Financials 2025 – Clarifo